Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer's Prevnar 13 Could Gain Edge With Vaccine Panel Review

Executive Summary

An endorsement from FDA's Vaccines and Related Biological Products Advisory Committee for Wyeth's (now Pfizer's) Prevnar 13 would be a positive step for the firm in its race against GlaxoSmithKline rival vaccine Synflorix to capture the next-generation pneumococcal vaccine market

You may also be interested in...



Prevnar 13 Faces Two Disparate Challenges At Advisory Committee

Next-generation pneumococcal vaccine failed to show non-inferiority on several serotypes, and there is little scientific consensus about the criteria for its second proposed indication, otitis media.

Prevnar 13 Faces Two Disparate Challenges At Advisory Committee

Next-generation pneumococcal vaccine failed to show non-inferiority on several serotypes, and there is little scientific consensus about the criteria for its second proposed indication, otitis media.

Growing Up: Vaccine Market Increasingly Targets Adults

This past spring, the executive team at 1Intercell AG received the proverbial shot in the arm. After a decade of research and testing, their Ixiaro vaccine for combating Japanese encephalitis was approved by the FDA and then recommended by the Advisory Committee on Immunization Practices

Topics

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel